CRISPR Therapeutics (CRSP) announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, CMO, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi (SNY). In addition, the Company also announced the promotion of Julianne Bruno, M.B.A., to Chief Operating Officer, COO, effective as of May 23, 2024. She currently serves as the Company’s Senior Vice President and Head of Programs & Portfolio Management.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood’s ARK Investment bought 86.9K shares of Crispr Therapeutics today
- Cathie Wood’s ARK Investment bought 90K shares of Crispr Therapeutics today
- BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
- Crispr Therapeutics price target lowered to $95 from $102 at Oppenheimer
- CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference